CUPERTINO, Calif., April 27,
2022 /PRNewswire/ -- DURECT Corporation (Nasdaq:
DRRX) today announced that it will report its first quarter 2022
financial results and host a conference call after the market close
on Wednesday, May 4, 2022.
Wednesday, May 4 @
4:30pm Eastern Time / 1:30pm Pacific Time
Toll Free:
1-800-285-6670
International:
713-481-1320
Conference ID:
13729654
Webcast:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=6RVdxB8I
About DURECT Corporation
DURECT is a
biopharmaceutical company committed to transforming the treatment
of acute organ injury and chronic liver diseases by advancing novel
and potentially lifesaving therapies based on its endogenous
epigenetic regulator program. Larsucosterol (also known as
DUR-928), DURECT's lead drug candidate, binds to and inhibits the
activity of DNA methyltransferases (DNMTs), epigenetic enzymes
which are elevated and associated with hypermethylation found in
alcohol-associated hepatitis (AH) patients. Larsucosterol is in
clinical development for the potential treatment of AH, for which
FDA has granted a Fast Track Designation; non-alcoholic
steatohepatitis (NASH) is also being explored. In addition,
POSIMIR® (bupivacaine solution) for infiltration use, a non-opioid
analgesic utilizing the innovative SABER® platform technology, is
FDA-approved and has been exclusively licensed to Innocoll
Pharmaceuticals for development and commercialization in
the United States. For more
information about DURECT, please
visit www.durect.com and follow us on
Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement.
The
statements in this press release regarding clinical development of
larsucosterol (DUR-928) for potential treatment of AH, the
potential to develop larsucosterol for NASH or other
indications, the expected commercial launch of POSIMIR by
Innocoll and potential future payments we may receive from Innocoll
are forward-looking statements involving risks and uncertainties
that can cause actual results to differ materially from those in
such forward-looking statements. Potential risks and uncertainties
include, but are not limited to, the risks that the AHFIRM trial of
larsucosterol in AH takes longer to conduct than anticipated due to
COVID-19 or other factors, the risk that ongoing and future
clinical trials of larsucosterol do not confirm the results
from earlier clinical or pre-clinical trials, or do not demonstrate
the safety or efficacy or the life-saving potential of
larsucosterol in a statistically significant manner,
risks that Innocoll may not commercialize POSIMIR successfully, if
at all, and risks related to our ability to obtain capital to fund
operations and expenses. Further information regarding these and
other risks is included in DURECT's annual report on Form 10-K
filed on March 8, 2022 with the
Securities and Exchange Commission under the heading "Risk
Factors." The 10-K and other public filings are available on
our website www.durect.com under the "Investors" tab.
NOTE: POSIMIR® is a trademark of Innocoll Pharmaceuticals, Ltd.
in the U.S. and a trademark of DURECT Corporation outside of the
U.S. SABER® is a trademark of DURECT Corporation. Other
referenced trademarks belong to their respective
owners. Larsucosterol (DUR-928) is an investigational drug
candidate under development and has not been approved for
commercialization by the U.S. Food and Drug
Administration or other health authorities for any
indication.
View original
content:https://www.prnewswire.com/news-releases/durect-corporation-to-announce-first-quarter-2022-financial-results-and-provide-business-update-on-may-4-301534658.html
SOURCE DURECT Corporation